G1 Therapeutics, Inc.

NasdaqGS:GTHX Rapport sur les actions

Capitalisation boursière : US$378.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

G1 Therapeutics Gestion

Gestion contrôle des critères 2/4

Le PDG G1 Therapeutics est Jack Bailey, nommé en Jan2021, a un mandat de 3.67 ans. La rémunération annuelle totale est $ 3.25M, composée du salaire de 24.5% et des bonus 75.5%, y compris les actions et options de la société. détient directement 0.37% des actions de la société, d'une valeur de $ 1.40M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.7 ans et 6 ans.

Informations clés

Jack Bailey

Directeur général

US$3.3m

Rémunération totale

Pourcentage du salaire du PDG24.5%
Durée du mandat du directeur général3.7yrs
Propriété du PDG0.4%
Durée moyenne d'occupation des postes de direction3.7yrs
Durée moyenne du mandat des membres du conseil d'administration6yrs

Mises à jour récentes de la gestion

Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Jun 07
Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Recent updates

There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise

Jul 26
There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise

G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty

Jun 24

Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Jun 07
Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

May 28
Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 04
G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape

Mar 22

Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

Feb 27
Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

Feb 06
Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Jan 04
G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

Jun 08
Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

May 08
New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts

Nov 04
The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts

G1 Therapeutics: Catalysts Stacking

Oct 20

G1 Therapeutics: Building A Franchise

Sep 29

Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)

Aug 04
Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)

G1 Therapeutics Q2 2022 Earnings Preview

Aug 02

G1 Therapeutics: Take Advantage Of The November Data

Jul 22

Analyse de la rémunération des PDG

Comment la rémunération de Jack Bailey a-t-elle évolué par rapport aux bénéfices de G1 Therapeutics?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

-US$45m

Mar 31 2024n/an/a

-US$31m

Dec 31 2023US$3mUS$795k

-US$48m

Sep 30 2023n/an/a

-US$71m

Jun 30 2023n/an/a

-US$78m

Mar 31 2023n/an/a

-US$126m

Dec 31 2022US$3mUS$764k

-US$148m

Sep 30 2022n/an/a

-US$154m

Jun 30 2022n/an/a

-US$171m

Mar 31 2022n/an/a

-US$171m

Dec 31 2021US$9mUS$735k

-US$148m

Sep 30 2021n/an/a

-US$134m

Jun 30 2021n/an/a

-US$103m

Mar 31 2021n/an/a

-US$95m

Dec 31 2020US$2mn/a

-US$99m

Rémunération vs marché: La rémunération totale de Jack ($USD 3.25M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 2.40M ).

Rémunération et revenus: La rémunération de Jack a augmenté alors que l'entreprise n'est pas rentable.


PDG

Jack Bailey (59 yo)

3.7yrs

Titularisation

US$3,250,658

Compensation

Mr. John E. Bailey, also known as Jack, Jr. has been Director at G1 Therapeutics, Inc. since March 12, 2020. He serves as President and Chief Executive Officer at G1 Therapeutics Inc. since January 1, 2021...


Équipe de direction

NomPositionTitularisationCompensationPropriété
John Bailey
CEO, President & Director3.7yrsUS$3.25m0.37%
$ 1.4m
Rajesh Malik
Chief Medical Officer10.2yrsUS$1.11m0.17%
$ 625.3k
Mark Avagliano
Chief Business Officer5.2yrsUS$1.17m0.049%
$ 186.1k
John Umstead
Chief Financial Officer1.5yrspas de données0.037%
$ 138.2k
Terry Murdock
Chief Operating Officer5.7yrsUS$2.75m0.040%
$ 151.2k
William Roberts
Vice President of Investor Relations & Corporate Communications3.7yrspas de donnéespas de données
Monica Thomas
Chief Legal & People Officer1.3yrspas de données0.013%
$ 49.0k
Evan Hicks
Vice President of Marketingno datapas de donnéespas de données
Andrew Perry
Chief Commercial Officer3.1yrsUS$3.39m0.027%
$ 101.8k
Jeff Macdonald
Senior Director of Investor Relations & Corporate Communicationsno datapas de donnéespas de données

3.7yrs

Durée moyenne de l'emploi

55yo

Âge moyen

Gestion expérimentée: L'équipe de direction de GTHX est considérée comme expérimentée (ancienneté moyenne 3.7 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
John Bailey
CEO, President & Director4.5yrsUS$3.25m0.37%
$ 1.4m
Seth Rudnick
Member of Clinical Advisory Boardno dataUS$456.29kpas de données
Glenn Muir
Independent Director9yrsUS$172.85k0.35%
$ 1.3m
Joseph Bailes
Scientific & Clinical Advisorno datapas de donnéespas de données
George Demetri
Scientific & Clinical Advisorno datapas de donnéespas de données
Cynthia Flowers
Independent Director6.3yrsUS$162.85k0.030%
$ 113.6k
Garry Nicholson
Independent Chairman of the Board6yrsUS$195.35k0.027%
$ 102.9k
Gary Lyman
Scientific & Clinical Advisorno datapas de donnéespas de données
Norman Sharpless
Director2.2yrsUS$135.35k0%
$ 0
Kwok-Kin Wong
Co-Founder & Member of Scientific Advisory Boardno datapas de donnéespas de données
Donald McDonnell
Scientific & Clinical Advisorno datapas de donnéespas de données
Geoffrey Shapiro
Scientific & Clinical Advisorno datapas de donnéespas de données

6.0yrs

Durée moyenne de l'emploi

67yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de GTHX sont considérés comme expérimentés (ancienneté moyenne 6 ans).